Article ; Online: Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants.
Expert opinion on pharmacotherapy
2023 Volume 24, Issue 6, Page(s) 747–762
Abstract: Introduction: Respiratory syncytial virus (RSV) is a common respiratory virus with a huge impact on patients, the healthcare system, and society worldwide. Very few effective chances of prevention and treatment of RSV infection are available.: Areas ... ...
Abstract | Introduction: Respiratory syncytial virus (RSV) is a common respiratory virus with a huge impact on patients, the healthcare system, and society worldwide. Very few effective chances of prevention and treatment of RSV infection are available. Areas covered: In this paper, knowledge on RSV characteristics and current stage of development of new pharmacological measures against this virus are discussed. Expert opinion: In recent years, the structure of RSV was explored in depth and several pharmacologic measures potentially effective for prevention and treatment of RSV infection and disease were identified. These new measures have the aim to overcome the limitations of palivizumab and ribavirin. Strategies to protect infants through immunization of pregnant women and/or the use of more effective monoclonal antibodies were developed. At the same time, it was defined which vaccines could be administered to unprimed infants to avoid the risk of enhanced respiratory disease and which vaccines could be effective in older patients and in subjects with reduced immune system efficiency. Finally, a great number of new antiviral drugs targeting the RSV proteins that allow RSV entering host cells or regulate virus replication were produced. Although further studies are needed, some preparations seem effective and safe, making the future of RSV infection prevention and treatment less gloomy. |
---|---|
MeSH term(s) | Infant ; Humans ; Female ; Pregnancy ; Aged ; Respiratory Syncytial Virus Infections/drug therapy ; Respiratory Syncytial Virus Infections/prevention & control ; Palivizumab/therapeutic use ; Antiviral Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Respiratory Syncytial Virus, Human |
Chemical Substances | Palivizumab (DQ448MW7KS) ; Antiviral Agents ; Antibodies, Monoclonal |
Language | English |
Publishing date | 2023-04-06 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 2001535-5 |
ISSN | 1744-7666 ; 1465-6566 |
ISSN (online) | 1744-7666 |
ISSN | 1465-6566 |
DOI | 10.1080/14656566.2023.2197590 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5130: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.